Executive Summary

During this era, biotechnology evolved from understanding of biological molecules to engineering of life itself. The convergence of molecular biology, genetics, and technology has created unprecedented opportunities to address global challenges in healthcare, agriculture, and environmental sustainability.

• From Reading to Writing Genomes: The journey from sequencing DNA (reading) to synthesizing and editing it (writing) represents a fundamental shift. CRISPR and synthetic biology enable precise genetic modifications that were unimaginable decades ago.
• Democratization of Technology: Tools like PCR and CRISPR, once available only to specialized labs, have become accessible to small companies, academic labs, and even hobbyists. This democratization accelerates innovation while raising governance challenges.
• Convergence: Biotechnology increasingly integrates with computer science (bioinformatics, AI), nanotechnology (drug delivery), and engineering (synthetic biology), creating powerful hybrid approaches.
• Therapeutic Revolution: Gene therapies, cell therapies, mRNA vaccines, and CRISPR treatments are transforming medicine from treating symptoms to correcting underlying genetic and molecular causes of disease.
• Ethical Evolution: Each technological advance—from IVF to cloning to genome editing—has prompted society to grapple with profound ethical questions about the appropriate use of biological knowledge and power.
• Global Impact: Biotechnology increasingly addresses global challenges: developing pandemic vaccines in months rather than years, engineering crops for climate resilience, and creating sustainable biomanufacturing processes.

The pace of change continues to accelerate, with AI, machine learning, and improved genome editing tools promising even more profound capabilities. As biotechnology’s power grows, so does the importance of thoughtful governance, ethical reflection, and equitable access to ensure these technologies benefit all of humanity while respecting the complexity and value of life itself.

Introduction

There were two key events that have come to be seen as scientific breakthroughs beginning the era that would unite genetics with biotechnology: One was the 1953 discovery of the structure of DNA by Watson and Crick, and the other was the 1973 discovery by Cohen and Boyer of a recombinant DNA technique by which a section of DNA was cut from the plasmid of an E. coli bacterium and transferred into the DNA of another. Popularly referred to as “genetic engineering,” this became the basis of biotechnology.

A Chronology Of Biotechnology’s Modern Era

This chronology traces the pivotal moments that have shaped biotechnology from 1945 to the present day, documenting how theoretical discoveries evolved into practical applications that now touch every aspect of human life. From the foundational work of Watson and Crick to the revolutionary CRISPR-Cas9 system, from the birth of recombinant DNA technology to the creation of synthetic organisms, each milestone has built upon previous achievements while opening new frontiers of possibility. As we stand at the threshold of even more profound capabilities—from personalized medicine to engineered ecosystems—understanding this historical trajectory becomes essential for navigating the future of biotechnology and its implications for humanity.

The Molecular Revolution Begins (1945-1960)

• 1945: Rosalind Franklin earns her PhD in physical chemistry from Cambridge University with her dissertation “The physical chemistry of solid organic colloids with special reference to coal.” Her work on coal structure during World War II had demonstrated sophisticated understanding of molecular architecture using X-ray diffraction techniques—skills she would later apply to biological molecules with profound consequences.
• 1947-1950: Franklin moves to Paris as a postdoctoral researcher at the Laboratoire Central des Services Chimiques de l’État, working under Jacques Mering. During these years, she becomes an accomplished X-ray crystallographer, mastering techniques for analyzing the structure of imperfect crystals. This expertise positions her to make crucial contributions to understanding DNA structure when she returns to England.
• 1950: American biochemist Erwin Chargaff discovers critical patterns in DNA composition: in any double-stranded DNA sample, the amount of adenine equals thymine, and the amount of guanine equals cytosine. These “Chargaff’s rules” provide essential clues about DNA structure, though Chargaff himself doesn’t initially recognize their full significance for understanding the double helix.
• 1951: American cell biologist George Gey establishes the HeLa cell line from cervical cancer cells taken from Henrietta Lacks without her knowledge or consent. These become the first immortal human cells grown in culture, revolutionizing medical research by providing a standardized model for studying human cell biology, viral infection, drug testing, and cancer. The ethical issues surrounding their origin spark important conversations about informed consent that continue today.
• 1952: American geneticists Alfred Hershey and Martha Chase conduct elegant experiments using radioactive labeling to prove conclusively that DNA, not protein, carries genetic information. Using bacteriophages (viruses that infect bacteria), they demonstrate that DNA enters bacterial cells during infection while protein coats remain outside, settling a fundamental question about heredity’s molecular basis.
• 1953: On April 25, James Watson and Francis Crick publish their landmark one-page paper “Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid” in Nature, revealing DNA’s double helix structure. Their model, based heavily on Rosalind Franklin’s X-ray crystallography data (particularly Photo 51) and Chargaff’s rules, explains how genetic information is stored and replicated. The understated conclusion—”It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material”—marks one of the most significant scientific breakthroughs of the 20th century.
• 1955: American virologist Jonas Salk develops the first effective polio vaccine using killed poliovirus grown in mammalian cell culture. This triumph of cell culture technology leads to mass vaccination campaigns that dramatically reduce polio incidence worldwide, demonstrating the power of biotechnology for public health.
• 1956: American biochemist Arthur Kornberg isolates DNA polymerase I from Escherichia coli bacteria, the first enzyme shown to synthesize DNA. This discovery reveals the enzymatic machinery that cells use to replicate their genetic material.
• 1958: American geneticists Edward Tatum and Joshua Lederberg receive the Nobel Prize in Physiology or Medicine for demonstrating that genes regulate cellular metabolism by producing specific enzymes, and for discovering bacterial conjugation (genetic recombination in bacteria). Their work establishes that genetic principles discovered in simpler organisms apply broadly across life.
• 1959: Arthur Kornberg synthesizes DNA in a test tube for the first time, demonstrating that DNA replication can occur outside living cells when provided with the right enzymes, building blocks, and template DNA. This achievement shows that biological processes can be reconstructed in vitro.
• 1960: The first automatic protein sequencer is developed, enabling researchers to determine the amino acid sequences of proteins more efficiently. French scientists François Jacob, Jacques Monod, and colleagues discover messenger RNA (mRNA), the intermediary molecule that carries genetic information from DNA to the protein-synthesis machinery, filling a crucial gap in understanding how genes work.

Decoding The Genetic Blueprint (1960-1973)

• 1961: François Jacob and Jacques Monod propose the concept of the operon—a cluster of genes regulated together—based on their work with the lac operon in E. coli. This elegant model explains how bacteria regulate gene expression in response to environmental conditions and establishes fundamental principles of genetic regulation.
• 1962: Scientists determine that human DNA is approximately 99% similar to that of chimpanzees and gorillas, revealing the close evolutionary relationship among great apes and establishing molecular evidence for human evolutionary origins.
• 1964: American biologist Howard Temin predicts the existence of reverse transcriptase, an enzyme that synthesizes DNA from RNA templates—contradicting the prevailing “central dogma” that information flows only from DNA to RNA to protein. His hypothesis is initially met with skepticism.
• 1966: After years of intensive research by multiple laboratories, the genetic code is fully deciphered. Scientists establish which combinations of three RNA nucleotides (codons) specify each of the 20 amino acids used in proteins, revealing the universal language of life.
• 1967: DNA ligase, the enzyme that joins DNA fragments together, is used for the first time in laboratory experiments. This enzyme becomes essential for recombinant DNA technology.
• 1968: American microbiologist Hamilton Smith and colleagues discover restriction enzymes (restriction endonucleases) that cut DNA at specific recognition sequences. These molecular scissors become fundamental tools for genetic engineering.
• 1969: The first measles vaccine using attenuated virus is developed, building on earlier vaccine development principles.
• 1970: Restriction enzymes are isolated, characterized, and made widely available to researchers. American biochemist Har Gobind Khorana leads the first complete chemical synthesis of a gene, demonstrating that genes can be built from scratch using chemical methods.
• 1971: Howard Temin and David Baltimore independently isolate and characterize reverse transcriptase from retroviruses, proving Temin’s prediction correct. This discovery transforms understanding of RNA viruses (including HIV) and provides a crucial tool for molecular biology—making DNA copies of RNA templates.
• 1973: Stanford University biochemist Stanley Cohen and University of California San Francisco biochemist Herbert Boyer successfully perform the first recombinant DNA experiment. Meeting at a conference in Hawaii in 1972, they recognized that Boyer’s expertise with the restriction enzyme EcoRI complements Cohen’s work with plasmids. In 1973, they successfully inserted DNA from an African clawed frog into E. coli bacteria using a genetically engineered plasmid as a vector. Their landmark paper “Construction of Biologically Functional Bacterial Plasmids In Vitro” (November 1973) demonstrates that DNA from completely different species can be combined and replicated in bacteria. This achievement launches the biotechnology industry and establishes the foundation for genetic engineering.

Birth Of The Biotechnology Industry (1974-1990)

• 1974: Scientists develop the first biocement using bacterial processes for industrial applications, showing how microorganisms can be harnessed to produce construction materials.
• 1975: Georges Köhler and César Milstein develop a method for producing monoclonal antibodies—identical antibodies that recognize a single antigen. By fusing antibody-producing B cells with immortal myeloma cells, they create “hybridoma” cells that continuously produce specific antibodies. This technology revolutionizes diagnostics, research, and eventually leads to targeted cancer therapies. The Asilomar Conference brings together molecular biologists, lawyers, and physicians in Pacific Grove, California, to establish voluntary guidelines for recombinant DNA research. This unprecedented self-regulation addresses concerns about potential biohazards and establishes principles for responsible conduct of genetic engineering research.
• 1976: Molecular hybridization techniques are first used for prenatal diagnosis of alpha thalassemia, enabling detection of genetic diseases before birth and opening the era of prenatal genetic testing.
• 1977: British biochemist Frederick Sanger and colleagues sequence the complete genome of bacteriophage Phi X 174 (5,386 base pairs), the first complete genome of any organism ever sequenced. Sanger’s “chain termination” sequencing method became the standard technique for DNA sequencing for decades.
• 1978: Scientists at the University of North Carolina demonstrate that specific mutations can be introduced at precise locations in DNA (site-directed mutagenesis), enabling researchers to study how individual genetic changes affect protein function. Louise Brown, the world’s first “test-tube baby,” is born in England through in vitro fertilization (IVF) developed by Robert Edwards and Patrick Steptoe. This achievement launches assisted reproductive technology and earns Edwards the 2010 Nobel Prize. Genentech scientists produce recombinant human insulin in bacteria, the first synthesis of a human hormone in microorganisms, proving that bacteria can be engineered to manufacture medically important proteins.
• 1980: The U.S. Supreme Court rules 5-4 in Diamond v. Chakrabarty that genetically modified organisms can be patented, holding that “anything under the sun that is made by man” is patentable subject matter. This landmark decision enables the commercialization of biotechnology by allowing companies to protect their genetically engineered organisms. The U.S. Patent and Trademark Office awarded a patent to Cohen and Boyer for their gene cloning method, administered by Stanford and UCSF. The universities license the technology non-exclusively, and over 470 companies eventually pay licensing fees, demonstrating how university research can generate significant revenue while enabling broad scientific progress.
• 1981: Scientists at Ohio University create the first transgenic animals by inserting foreign DNA into mouse embryos, demonstrating that genes can be stably introduced into animals and passed to offspring. Chinese scientists successfully clone a golden carp, marking an early achievement in vertebrate cloning.
• 1982: The FDA approves Humulin, genetically engineered human insulin produced by bacteria, as the first biotechnology drug to reach the market. Manufactured by Genentech and marketed by Eli Lilly, Humulin represents a breakthrough for millions with diabetes and validates commercial biotechnology.
• 1983: American biochemist Kary Mullis invents the Polymerase Chain Reaction (PCR), a technique that amplifies specific DNA sequences exponentially. By repeatedly cycling through heating and cooling steps with special enzymes and primers, PCR can produce millions of copies of a DNA segment from a tiny starting sample. This revolutionary tool transforms molecular biology, forensics, medical diagnostics, and countless other fields. Mullis received the 1993 Nobel Prize in Chemistry. Scientists discover the first genetic markers for specific inherited diseases, enabling predictive genetic testing and laying groundwork for personalized medicine.
• 1984: British geneticist Alec Jeffreys discovers DNA fingerprinting (genetic profiling), recognizing that certain repetitive DNA sequences vary greatly among individuals. This technique revolutionizes forensic science, paternity testing, and criminal investigations.
• 1985: Researchers identify a genetic marker for cystic fibrosis on chromosome 7, bringing genetic testing for this common hereditary disease within reach.
• 1986: The FDA approves the first therapeutic monoclonal antibody for preventing organ transplant rejection, demonstrating the medical potential of antibody technology developed by Köhler and Milstein.
• 1987: British police achieve the first criminal conviction based on DNA fingerprinting evidence, establishing genetic evidence as a powerful forensic tool.
• 1988: Harvard University receives the first U.S. patent for a genetically modified animal—the OncoMouse, engineered to carry a cancer-predisposing gene for research purposes. This controversial patent raises ethical questions about patenting higher life forms.
• 1989-1990: The Human Genome Project is proposed and officially launches with James Watson as its first director, aiming to sequence all three billion base pairs of human DNA. This ambitious international effort, expected to take 15 years and cost $3 billion, represents the largest biological research project ever undertaken. In 1990, the first human gene therapy trial began for adenosine deaminase deficiency (ADA-SCID), a severe immune disorder. Though this specific approach has limited success, it establishes proof of concept for treating genetic diseases by introducing functional genes.

Genomics & Gene Therapy Emerge (1990-2005)

• 1993: Spanish microbiologist Francisco Mojica first systematically characterizes unusual repetitive DNA sequences in archaea—sequences that will later be identified as part of the CRISPR system, though their function remains mysterious for years.
• 1995: Craig Venter’s team at The Institute for Genomic Research sequences the complete genome of Haemophilus influenzae (1.8 million base pairs), the first complete genome of a free-living organism. This achievement demonstrates “shotgun sequencing” and shows that whole-genome sequencing is practical.
• 1996: On July 5, Dolly the sheep is born at the Roslin Institute in Scotland, cloned from an adult somatic cell by Ian Wilmut and colleagues. Dolly’s birth proves that differentiated adult cells can be reprogrammed to create an entirely new organism, challenging biological dogma and sparking intense debates about cloning ethics. Dolly lived until 2003 and produced healthy offspring.
• 1997: Polly the sheep is born, genetically modified to produce human clotting factor IX in her milk. This demonstrates “pharming”—using transgenic animals as bioreactors to produce therapeutic proteins.
• 1998: Craig Venter founded Celera Genomics as a private company to sequence the human genome using shotgun sequencing, creating competition with the public Human Genome Project and accelerating progress.
• 1999: Researchers complete the sequence of human chromosome 22, the first human chromosome fully sequenced, comprising 48 million base pairs.
• 2000: The Human Genome Project and Celera Genomics jointly announce completion of a “rough draft” of the human genome sequence, covering about 90% of the genome. This milestone comes years ahead of the original schedule.
• 2001: The complete human genome sequences are published simultaneously by the public consortium (in Nature) and Celera Genomics (in Science), revealing that humans have approximately 30,000-40,000 genes (later revised down to about 20,000-25,000). This achievement transforms biology and medicine by providing the complete genetic blueprint of our species.
• 2002: Rice becomes the first crop to have its complete genome decoded, advancing agricultural biotechnology and providing a model for understanding plant genetics.
• 2003: The Human Genome Project is officially completed, with 99.99% accuracy in sequencing the three billion base pairs of human DNA. The project finishes two years ahead of schedule and under budget, establishing genomics as a mature science and spawning numerous applications in medicine, agriculture, and research.
• 2005: Scientists demonstrate that zinc-finger nucleases—engineered proteins that bind specific DNA sequences and cut them—can be used to modify genetic mutations in human cells. This establishes an early form of precise genome editing.

Synthetic Biology & Precision Medicine (2005-2017)

• 2006: Japanese scientist Shinya Yamanaka creates induced pluripotent stem cells (iPSCs) by reprogramming adult mouse skin cells with just four genes. This breakthrough eliminates the need for embryonic stem cells and creates patient-specific stem cells for research and potentially therapy. Yamanaka received the 2012 Nobel Prize for this work.
• 2007: James Watson’s complete genome is sequenced and released publicly, demonstrating that individual genome sequencing is becoming practical and heralding the era of personalized genomics.
• 2008: Craig Venter’s team creates the first completely synthetic bacterial genome—a laboratory-made copy of the Mycoplasma genitalium genome (583,000 base pairs)—demonstrating that genomes can be chemically synthesized from scratch.
• 2010: Venter’s team creates “Synthia”—Mycoplasma mycoides JCVI-syn1.0—the first self-replicating synthetic organism. By transplanting a completely synthetic genome into a cell, they create a bacterium controlled entirely by man-made DNA, marking a milestone in synthetic biology. The FDA approves Provenge (sipuleucel-T), the first therapeutic cancer vaccine, for prostate cancer. This personalized immunotherapy uses a patient’s own immune cells to fight cancer.
• 2011: TALENs (Transcription Activator-Like Effector Nucleases) enter clinical trials, providing another tool for precise genome editing. French microbiologist Emmanuelle Charpentier discovers tracrRNA, a key component that works with CRISPR and Cas9 to target and cut specific DNA sequences, unraveling the mechanism of bacterial adaptive immunity.
• 2012: Charpentier and American biochemist Jennifer Doudna publish their seminal paper in Science demonstrating that the CRISPR-Cas9 system can be programmed to cut any DNA sequence by simply changing a short guide RNA. This revolutionary discovery transforms genome editing from a laborious process into something simple, precise, and accessible to virtually any laboratory, launching the CRISPR revolution.
• 2013: Feng Zhang at the Broad Institute adapts CRISPR-Cas9 for genome editing in mammalian cells, demonstrating its potential for human medicine. His work, published in Science, shows CRISPR can efficiently edit human cell genomes. The first CRISPR clinical trials begin, testing the technology’s safety and efficacy.
• 2015: Chinese scientists report creating the first gene-edited human embryos (non-viable), using CRISPR to attempt correcting a disease-causing mutation. This controversial work sparks intense ethical debates about germline editing and leads to calls for a global moratorium on editing viable human embryos.
• 2016: The FDA approves the first allogeneic cord blood therapy, using donor stem cells from umbilical cord blood for treating blood disorders.
• 2017: The FDA approves Kymriah (tisagenlecleucel), the first CAR-T cell therapy for cancer. This treatment engineers a patient’s own T cells to express chimeric antigen receptors that recognize and destroy cancer cells, achieving remarkable results in previously untreatable leukemia and lymphoma. The FDA approves Luxturna (voretigene neparvovec), the first gene therapy for an inherited disease in the U.S. Luxturna treats inherited retinal dystrophy by delivering a functional copy of the RPE65 gene directly to retinal cells, restoring vision in many patients.

The CRISPR Era & Convergence Of Technologies (2018-Present)

• 2018: Chinese scientist He Jiankui announces the birth of twin girls whose genomes he edited as embryos using CRISPR, ostensibly to confer HIV resistance. This unauthorized experiment, conducted without proper ethical oversight, provoked international condemnation and He’s subsequent imprisonment, highlighting the urgent need for governance of powerful genetic technologies.
• 2019: The FDA approves Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy, at the time the most expensive drug ever approved ($2.1 million for a single treatment). This gene therapy delivers a functional copy of the SMN1 gene, treating a previously fatal childhood disease.
• 2020: Emmanuelle Charpentier and Jennifer Doudna receive the Nobel Prize in Chemistry for developing CRISPR-Cas9 genome editing, recognizing the transformative impact of their discovery. The COVID-19 pandemic spurs development of mRNA vaccines by Pfizer-BioNTech and Moderna. These vaccines, which provide genetic instructions for cells to produce the SARS-CoV-2 spike protein and trigger immunity, represent the first large-scale deployment of mRNA technology. Their rapid development (less than a year) and high efficacy validate decades of basic research and demonstrate biotechnology’s potential for responding to global health crises. Over 13 billion doses are administered worldwide by late 2023.
• 2021: Base editing and prime editing technologies advance, offering even more precise genetic modifications than standard CRISPR. Base editors can change single DNA letters without cutting DNA, while prime editors can insert, delete, or replace DNA sequences with greater precision and fewer errors.
• 2022: DeepMind’s AlphaFold predicts the three-dimensional structures of nearly all known proteins (over 200 million), solving a 50-year-old challenge in biology. This AI breakthrough accelerates drug discovery, protein engineering, and understanding of disease mechanisms by making protein structure prediction widely accessible.
• 2023: The FDA approves Casgevy (exagamglogene autotemcel), the first CRISPR-based therapy for treating sickle cell disease. This treatment uses CRISPR to edit patients’ stem cells, enabling production of fetal hemoglobin to compensate for defective adult hemoglobin. The approval validates CRISPR’s therapeutic potential and marks the beginning of the genome editing medicine era.
• 2024: The FDA approves CRISPR therapy for β-thalassemia (using the same Casgevy treatment), expanding CRISPR medicine to multiple genetic blood disorders. Gene editing treatments show increasing sophistication and efficacy.
• 2025: The biotechnology field continues rapid advancement across multiple fronts:
  • Synthetic Biology: Engineering cells with novel functions, creating biological circuits, and designing organisms for specific purposes (biomanufacturing, environmental remediation, biosensing)
  • mRNA Therapeutics: Building on COVID-19 vaccine success, developing mRNA treatments for cancer, rare diseases, and infectious diseases
  • Gene Editing: Improving CRISPR and developing new editing tools with greater precision, reduced off-target effects, and better delivery methods
  • Personalized Medicine: Increasing use of genomic information for tailoring treatments to individual patients
  • AI-Driven Discovery: Using machine learning for drug discovery, protein design, and predicting biological outcomes
  • Cell and Gene Therapies: Expanding treatments for cancer, genetic disorders, and regenerative medicine
  • Agricultural Biotechnology: Developing climate-resilient crops, improving nutritional content, and reducing environmental impact

Final Thoughts

The chronology of biotechnology’s modern era reveals a remarkable acceleration of discovery and application, particularly in the past two decades. What began as fundamental research into the nature of heredity has evolved into a sophisticated toolkit for manipulating life at the molecular level, and the progression from understanding DNA’s structure to editing genomes with precision, and from producing the first recombinant proteins to creating synthetic organisms, demonstrates humanity’s growing mastery over biological systems. Yet, we continue to be human – in the end, the future of biotechnology will likely be shaped by what we can do, not what we should do.

Thanks for reading!

References

[1] Rosalind Franklin – Wikipedia – https://en.wikipedia.org/wiki/Rosalind_Franklin

[2] Dr. Rosalind Franklin – Rosalind Franklin University – https://www.rosalindfranklin.edu/about/facts-figures/dr-rosalind-franklin/

[3] The History of DNA Timeline | DNA Worldwide – https://www.dna-worldwide.com/resource/160/history-dna-timeline

[4] Timeline | An Introduction to Biotechnology – https://www.biotechnology.amgen.com/timeline.html

[5] Sequencing Human Genome: the Contributions of Francis Collins and Craig Venter | Learn Science at Scitable – https://www.nature.com/scitable/topicpage/sequencing-human-genome-the-contributions-of-francis-686/

[6] Biotechnology in the Realm of History – PMC – https://pmc.ncbi.nlm.nih.gov/articles/PMC3178936/

[7] Francis Crick, Rosalind Franklin, James Watson, and Maurice Wilkins | Science History Institute – https://www.sciencehistory.org/education/scientific-biographies/james-watson-francis-crick-maurice-wilkins-and-rosalind-franklin/

[8] Biotechnology timeline: Humans have manipulated genes since the ‘dawn of civilization’ – Genetic Literacy Project – https://geneticliteracyproject.org/2023/10/30/biotechnology-timeline-humans-manipulating-genes-since-dawn-civilization/

[9] Timeline of biotechnology – Wikipedia – https://en.wikipedia.org/wiki/Timeline_of_biotechnology

[10] Timeline of Biotechnology | Encyclopedia MDPI – https://encyclopedia.pub/entry/37943

[11] History of biotechnology – Wikipedia – https://en.wikipedia.org/wiki/History_of_biotechnology

[12] Gene therapy history | GenePossibilities HCP – https://www.genepossibilitieshcp.com/gene-therapy-overview/gene-therapy-history

[13] Biotechnology timeline – https://www.abpischools.org.uk/topics/biotechnology/biotechnology-timeline/

[14] Human Genome Project – History of Molecular Biology and Biotechnology – LibGuides at Cold Spring Harbor Laboratory – https://cshl.libguides.com/c.php?g=474065&p=3243824

[15] The Human Genome Project – https://www.genome.gov/human-genome-project

[16] CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing – PMC – https://pmc.ncbi.nlm.nih.gov/articles/PMC9377665/

[17] Development of Luxturna Gene Therapy – Milestones In Retina – https://retinahistory.asrs.org/milestones-developments/the-history-and-development-of-luxturna-gene-therapy

[18] CRISPR Timeline | Broad Institute – https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-timeline

[19] John Craig Venter (1946- ) | Embryo Project Encyclopedia – https://embryo.asu.edu/pages/john-craig-venter-1946

[20] Dolly (sheep) – Wikipedia – https://en.wikipedia.org/wiki/Dolly_(sheep)

[21] Cloning Fact Sheet – https://www.genome.gov/about-genomics/fact-sheets/Cloning-Fact-Sheet

[22] The History of Cloning – https://learn.genetics.utah.edu/content/cloning/clonezone/

[23] Craig Venter – Wikipedia – https://en.wikipedia.org/wiki/Craig_Venter

[24] It’s alive! | Nature Reviews Microbiology – https://www.nature.com/articles/nrmicro2399

[25] mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications | Journal of Biomedical Science – https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00977-5

[26] CRISPR technology: A decade of genome editing is only the beginning | Science – https://www.science.org/doi/10.1126/science.add8643

[27] What is CRISPR? A bioengineer explains | Stanford Report – https://news.stanford.edu/stories/2024/06/stanford-explainer-crispr-gene-editing-and-beyond

[28] Questions and Answers about CRISPR | Broad Institute – https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/questions-and-answers-about-crispr

[29] FDA approves hereditary blindness gene therapy | Nature Biotechnology – https://www.nature.com/articles/nbt0118-6a

[30] Years later, a first-of-its-kind treatment shows the power, and limits, of gene therapy | BioPharma Dive – https://www.biopharmadive.com/news/luxturna-gene-therapy-eye-leber-lca/609832/

[31] First gene therapy for genetic disease approved – https://cen.acs.org/articles/95/web/2017/12/First-gene-therapy-genetic-disease.html

[32] Recent Advancement in mRNA Vaccine Development and Applications – PMC – https://pmc.ncbi.nlm.nih.gov/articles/PMC10384963/

[33] Build a Sustainable Vaccines Industry with Synthetic Biology – PMC – https://pmc.ncbi.nlm.nih.gov/articles/PMC7834237/

[34] The clinical progress of mRNA vaccines and immunotherapies | Nature Biotechnology – https://www.nature.com/articles/s41587-022-01294-2

[35] Biotechnology and Synthetic Biology | Stanford Emerging Technology Review – https://setr.stanford.edu/technology/biotechnology-synthetic-biology/2025

[36] Harnessing synthetic biology for advancing RNA therapeutics and vaccine design | npj Systems Biology and Applications – https://www.nature.com/articles/s41540-023-00323-3